GlomCon

GlomCon is a resource for the kidney community to exchange ideas, learn, educate, and collaborate on projects.
Membership via

[GlomCon @GlomCon]

🚨 NOW OPEN: Pre-Application for Rare Kidney Disease/Glomerular Disease Centers of Excellence! 🚨

Join exceptional institutions, clinics, and healthcare organizations to become designated Centers of Excellence.

🎯 What you'll gain:
✅ Access to premier fellowship programs
✅ Secure database platform for operational and research registry
✅ Exclusive director network meetings
✅ Free conference registration + educational resources
✅ Clinical trial support services
✅ Population health dashboards

🏥 Perfect for:
• Academic medical centers
• Nephrology Clinics
• Healthcare institutions serving rare kidney disease populations

📅 Timeline: Pre-applications open NOW | Framework release Fall 2025

Ready to elevate your rare kidney disease program? Apply today! 👇
https://t.co/jtjIODkINM

#RareKidneyDisease #GlomerularDisease #CentersOfExcellence #Nephrology #PatientCare

[GlomCon @GlomCon]

Who actually benefits from plasmapheresis? Amber Sanchez leads a two-part series of pheresis clinical workshop sessions.

Part 1 focuses on the practical, bedside engineering of vascular access, replacement fluids, and circuit safety. Part 2 tackles the PEXIVAS paradox in ANCA vasculitis, post-transplant FSGS recurrence, and evidence-based indications. #Plasmapheresis #Nephrology #GlomConHawaii2026 #ClinicalEvidence

[GlomCon @GlomCon]

Join GlomCon this Sunday

B and Plasma Cell-Targeting Therapies for Podocytopathies by Dr. Andrea Angeletti

ID: 817 4374 4653
Passcode: 202122

Sign up 👉 https://t.co/fxh2CVuWhy
#GlomCon

[Columbia Med CME @CUIMCMedCME]

Day 1 of the 49th Annual Columbia Renal Biopsy Course is packed with foundational and cutting-edge content! From Histopathology of the Glomerulus to current therapy of MCD & FSGS, Membranous Nephropathy updates, and C3G — this is where the latest in glomerular disease meets practical biopsy interpretation.
Join us in NYC or virtually https://t.co/wHpFUYW4FR
#RenalBiopsy #Nephrology #CME @AgnesFogo @ColumbiaMed @ColumbiaKidney @glomcon

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

Starting complement inhibitors but not sure how to handle #vaccination and #antibiotics? 🚨
This is one of those practical questions that keeps coming up in clinic. Lets chat about it 😄

#ERA #RareKidneyDiseases @ERAkidney @GlomCon

[GlomCon @GlomCon]

How do we validate anti-PLA2R kinetics as a surrogate trial endpoint?

@PolskiBarbara, Heather Reich, @fervenzaf , Manish Maski, Amit Sharma, and @VladoPerkovic debate the future of membranous nephropathy trial design.

#Membranous #ClinicalTrials #GlomConHawaii2026 #PrecisionMedicine

[GlomCon @GlomCon]

Deadline approaching: Submit your abstract to GlomCon Hawaii 2026 by June 10 📢

Accepted submissions will be notified by June 22 and may be featured as oral or poster presentations.

Learn more 👉 https://t.co/0xaMCf0LFa

#GlomConHawaii
#GlomCon

[GlomCon @GlomCon]

📢 The Rare Disease And Nephrology Research Training (RADIANT) Program is now accepting applications!

RADIANT Program is designed to teach foundational knowledge and skills in rare kidney disease research with a focus on clinical research in glomerular diseases.

Applications close on June 24.

🔗For more information, visit us at https://t.co/gxN0z95R6l

#GlomCon #RADIANTProgram #education #research #training #nephrology #clinicalresearch

[Izabela Zakrocka @IzabelaZakrocka]

Not only the IgA1: the role of IgA2 in the IgA nephropathy pathogenesis 🔬 Great data presented by Dr. Run Li and Dr. Lei Jiang @GlomCon

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

AI feedback vs. human feedback >> we put it to the test ⭐️
At @GlomCon Fellowship, we care about how we teach, not just what we teach. So we studied one of the most overlooked skills: giving great feedback.
See the details here👇
https://t.co/xi4GRwsMwH

[GlomCon @GlomCon]

Confronting the STARMEN hangover and rituximab resistance in membranous nephropathy: @fervenzaf , @SethiRenalPath , @GlassockJ , @LadanZand , @PolskiBarbara , and @nephrologista break down biomarker-guided dosing and anti-B and anti-plasma cell strategies.

#Membranous #Nephrology #GlomConHawaii2026 #Immunology #ClinicalReview

[Brian Rifkin, MD @brian_rifkin]

@GlomCon @poyanmehr I highly recommend if you can fit it your schedule. Many trainees don’t get enough exposure during fellowship to feel comfortable with GN diagnosis and management . Great to hear from the global experts in a field with rapidly changing therapeutics.

[GlomCon @GlomCon]

From trial efficacy to real-world effectiveness: @DanaRizk1 , Dustin Little, @jardine_meg , @Suceena , @willkidney , and Michael Walsh are leading a session on the design and future of Phase IV trials and registry-driven evidence in IgA nephropathy.

#IgAN #PhaseIV #RealWorldEvidence #GlomConHawaii2026 #Methodology

[GlomCon @GlomCon]

📢 The GlomCon Glomerular Disease Fellowship is now accepting applications!

Make sure you don't miss out on the chance to apply for the program, learn from top experts in the field, and engage in interactive workshops with them.

Join the GlomCon family by applying today!

🔗 Learn more: https://t.co/7XIfdsZrzq

@SaynaNorouzi @nephrologista @BetterCallSeeth
#GlomCon #glomconfellowship #GlomerularDisease #nephrology

[GlomCon @GlomCon]

From trial efficacy to real-world effectiveness: @DanaRizk1 , Dustin Little, @jardine_meg , @Suceena , @willkidney , and Michael Walsh are leading a session on the design and future of Phase IV trials and registry-driven evidence in IgA nephropathy.

#IgAN #PhaseIV #RealWorldEvidence #GlomConHawaii2026 #Methodology

[GlomCon @GlomCon]

📢 The GlomCon Glomerular Disease Fellowship is now accepting applications!

Make sure you don't miss out on the chance to apply for the program, learn from top experts in the field, and engage in interactive workshops with them.

Join the GlomCon family by applying today!

🔗 Learn more: https://t.co/7XIfdsZrzq

@SaynaNorouzi @nephrologista @BetterCallSeeth
#GlomCon #glomconfellowship #GlomerularDisease #nephrology

[GlomCon @GlomCon]

Achieving GN remission shouldn't come at the cost of safety.

@AKronbichler , @Nester1Carla , @DrBradleyDixon , @SaynaNorouzi , @KottonNelson , and @poyanmehr as they outline the ultimate safety checklist for modern immunosuppressive and complement therapies.

#PatientSafety #Nephrology #GlomConHawaii2026 #PreventiveMedicine

[GlomCon @GlomCon]

Why do we miss genetic kidney disease cases?

Ali Gharavi, Martin Pollak, @OpeyemiOlabisi8 , Anjay Rastogi, @Nester1Carla , and @SaynaNorouzi are leading the panel discussing genomic testing, VUS management, and precision therapeutics.

#KidneyGenetics #Genomics #Nephrology #GlomConHawaii2026 #RareDisease

[GlomCon @GlomCon]

How do we design clinical trials for a disease as heterogeneous as FSGS?

@PolskiBarbara, @PRomagnani , Ingeborg Bajema, Mohit Mathur, Dustin Little, Michael Walsh discuss endpoints, comparators, and biomarker enrichment.

#FSGS #ClinicalTrials #GlomConHawaii2026 #TrialMethodology

[GlomCon @GlomCon]

Welcome to the post-nephrin era! @PRomagnani , Steve Korbet, @AKronbichler , Mario Rubin, @JeanHouMD , and Neiha Arora break down the MCD-FSGS continuum and treatment options in new diagnosis and refractory disease.

#FSGS #MCD #Podocytes #GlomConHawaii2026 #KidneyImmunology

[GlomCon @GlomCon]

To biopsy or to bypass?

A stellar panel featuring @GlassockJ , @PepaSolerR , Mario Rubin, @NephRodby , @AnnetteBruchfe1 , and @d_r_waguespack debates the diagnostic necessity of tissue biopsy in the biomarker era.

#RenalBiopsy #Diagnostics #Nephrology #GlomConHawaii2026 #PrecisionCare